REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Filing of definitive proxy statement

MaxCyteAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250428:nRSb3259Ga&default-theme=true

RNS Number : 3259G  MaxCyte, Inc.  28 April 2025

 

 

 

 

MaxCyte Inc.

(ÒMaxCyteÓ or the ÒCompanyÓ)

 

Update on Proposed Cancellation of Admission of Common Stock to Trading on AIM
- Filing of definitive proxy statement with the SEC

 

ROCKVILLE, MD, LONDON, UK, 28 April 2025 Ñ MaxCyte, Inc., (NASDAQ: MXCT; LSE:
MXCT), a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and commercialization of
next-generation cell therapeutics, announces that, following its notice on 15
April 2025 of the CompanyÕs intention to cancel trading of its ordinary
shares on AIM, the Company intends to file a definitive proxy statement in
relation to seeking stockholder approval for the AIM Delisting and other
matters to be voted on at the annual meeting with the SEC later today.

 

The definitive proxy statement will be sent to stockholders and made available
on MaxCyteÕs website at https://investors.maxcyte.com
(https://investors.maxcyte.com) later today.

 

The Company will seek stockholder approval for the AIM Delisting at its annual
meeting of stockholders which will be held at 11.00 a.m. Eastern Time (4.00
p.m. UK time) on Wednesday 18 June 2025 at 9713 Key West Avenue, Suite 400,
Rockville, Maryland, 20850.

 

Updated Anticipated Timetable of Key Events

 

 Announcement of the AIM Delisting                                7.00 a.m. (UK time) on 15 April 2025
 Filing of the preliminary Proxy Statement with the SEC           After market close US time on 15 April 2025

 Voting record date                                               22 April 2025
 Filing of the definitive Proxy Statement with the SEC            28 April 2025

 Dispatch of the final Proxy Statement to stockholders            28 April 2025
 Deadline for proxy votes for the Annual Meeting                  17 June 2025
 Annual Meeting                                                   18 June 2025
 Announcement of results of Annual Meeting                         19 June 2025
 Last day of dealings in the Common Stock on AIM                  25 June 2025
 Cancellation of admission to trading on AIM of the Common Stock  7.00 a.m. (UK time) on 26 June 2025

 

Forward-Looking Statements

 

This announcement contains Òforward-looking statementsÓ within the meaning
of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended, including in respect
of the anticipated timeline of key events related to the proposed AIM
Delisting. All statements other than statements of historical fact contained
in this announcement are forward-looking statements. Forward-looking
statements usually relate to future events. Forward-looking statements are
often identified by the words Òbelieve,Ó Òexpect,Ó Òanticipate,Ó
Òplan,Ó Òintend,Ó Òforesee,Ó Òshould,Ó Òwould,Ó Òcould,Ó Òmay,Ó
and similar expressions, including the negative thereof. The absence of these
words, however, does not mean that the statements are not forward-looking.
These forward-looking statements are based on the CompanyÕs current
expectations, beliefs and assumptions concerning future developments and their
potential effect on the Company. While management believes that these
forward-looking statements are reasonable as and when made, there can be no
assurance that future developments affecting the Company will be those that it
anticipates.

 

All of the CompanyÕs forward-looking statements involve known and unknown
risks and uncertainties, some of which are significant or beyond its control
and involve assumptions that could cause actual results to differ materially
from the CompanyÕs historical experience and its present expectations. These
forward-looking statements are subject to risks and uncertainties, including,
among other things, risks that the stockholder vote for the AIM Delisting may
not be obtained and that the anticipated trading volume in the CompanyÕs
equity securities on Nasdaq may not materialise, as well as those risks and
uncertainties described in the CompanyÕs latest Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and other documents filed from time to time by
the Company with the SEC. The Company wishes to caution investors not to place
undue reliance on any forward-looking statements, which speak only as of the
date hereof. The Company undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise, except to the extent required by law.

 

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patientsÕ lives. We have spent more than 25 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond todayÕs processes to innovate
tomorrowÕs solutions. Our ExPERTª platform, which is based on our Flow
Electroporation¨ technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATxª, STxª, GTxª and VLx ª; a
portfolio of proprietary related processing assemblies or disposables; and
software protocols, all supported by a robust worldwide intellectual property
portfolio. By providing our partners with the right technology platform, as
well as scientific, technical and regulatory support, we aim to guide them on
their journey to transform human health. Learn more at maxcyte.com
(https://www.globenewswire.com/Tracker?data=E5yuyjzkzZo4wvqKx2w8-uT1PzbeAmsDuiSRpilmnVj24TGyATVX8wpaEmrU7b9Dov_W5D8ktDwmLd21LF26DEXMeBCszGxe7fKsvsIkp3_DoUuGt8AApiPb3gW2lXTlO4ArFWM0xvWiNY7_e3HUR25N5TCwd75OJNBfmAXRPL-o5ufeZumLPJGS8Tr2GOAHk7GNKyP375YkjrRIJ2f17lL-udYRUVy0P16uZn6I4Iw6huFrGT-w0BW6cpxU-jpPsQDf3RJHcmezdhPZRJC07eTXyb_SgexR-qzvc0cnrfAzOIXar-udApuulgzMHBhUi47rXb1ch7pdCX9Gv2zJXCTFcabO5qoKQyLo40IBDSguXYejfxYuv5Fa3vaoopyicC7aKF999UYk9rA87ENLGhoUK4hwd8447XOYjEm4cyH0GXzNfVdO163HieB6tmN_I3kbcwO62VBXa9MlGKkIluWE2f2_9erIlySFfGZREomfemQaz3aVojClgMPbj48BeyLu7nRiuA7EHEJtW-xD0YYpsShj6_Eflya9IMroQp3bw5ppAxVgS85F6RBJiahHPOR7c2L0AfXU5gqm9Yz7juljVuijfKrSPgFBe7Mt0hLgAH6IizakY5MNRFWFJDHZrffKCes5YdxjzEPr6Ac_co_sVJ8vYKXdGfZ_tu5JcJLw49yteTvp12vX7FwZa1zZaqFefUZF84g1CB7Tqa3HY-Q3ba_j1r40NR8AcejjOQMevvQpC4P3klrzcN6aJkxebSKvxHhcyyuirezqRbIvnZo-AH0RmlzAbRaXzq82TGfuY-MfZHLgskERj2RhOG_lyvjXnANbtEnCmP5Ggjgy8nOwl7HlKe4DWEgKy_yi0gMoRlqEL0DfFEM2Tsb-91FJbPxBdRVdNF3EfEdod3UZhw==)
 and follow us on X
(https://www.globenewswire.com/Tracker?data=mRsj5bEOqw2SK3Xpgr3ysqDBCVhhRJpS6iq1Fqto8RymFZEXNc8JUYB0bc17B-vF_17rULM3iYY0RTk2sMOyGGEYST62XSLhhijOrCq7C-8giesGUyA8zpk2I57tRUHi4Kx77vnIEvHGEyODMG4O1NiY_CkGI2-8T6ozqlNJhWRvFYKQ4qWj-XEI_PX67yiyQY4V3mSzkV1HXZLEBIg_5MXW0TqHRuNzT4zX4hy-yQI8einNEGgGFDp9Wm5rx3dJL4LPeXR-9vIHL1b7WBVU-uCqkkKK-zHO0bgoPM11U0ZH-KAWM9M2dB9BXvXl02n_JmJpVcFuWPw3qCXRaHktBHMbPHCzq1z3CAd6LwYrsc4Hp3L1DONJSpYWFW75EPVgPFi21oiKdekjWD9dDwBn_vTVDm0SNMRL3vdjvJwz4i2iECqJbZc3PD9dSkwe1-muN1F6xBIxv0RjNYOjR8z57oUIiH06-8vFJtCfezRZlyBKViPX02tBF-WCGmZ3Jn6mz-XX0xNhRpMPnFkS3WaT70M3MIg6Gd2VKrrb2Qre20Uqfxth-t_ntIQT3h0sL1sB1ciVc9NjCsISXU4RonSPM2ZOpjB8QbR65CoO6vG4a_KaGw_vpUiTcDYOpKtdjkXdvSEnd7o1V27g6keAK-UvCYXmad6WJAU-wLRMx2jcztbjOBgYU_Z8wYLn9Wy8mPn5uC0xI3mVKCedgnatE8v3wICQtPLDZIz7h6LPJNYBNP2FBl_i7-sLItwj53BbsjFKqRPi_ohGC2DHa8pUwSuD-cFUQwjmRlh_qZqeLKaExI-F_0kVwdJE5K63U2J7PmZuoE_BAPpXypiwxzLWztEyf9p45P5c8CGk5Y_9HGt5vr_7QND40MEHClHHcWoYQa-6obDp0nUQQKN8hkxxuP-7zA==)
 and LinkedIn
(https://www.globenewswire.com/Tracker?data=-2ctx2Ny_PKWoVv3RDatHzZXsmWhXYdNOxu59Fvuv1vMeqWyezc9OAUIDjySd2Og1V2isK_TemOpb7qnTNWn4wJVoZUX8U7uJFFbiXwIov0AKsB2-auQh5xbZXpkTp-fVxGyFv8B1s4fA1iEqZoCe3oQ-AkkG_jOXrI15jUcmBU-zr2N4PGitfbkAfLDRyZDAK4caGQKbl7oKb1LZoq4Cc05MRbS5dR8YlT3qVt1eaEd-p4N2ktXcu7P7PaDuRYWCwtVa2P6FXjf3h35gsNf6AGq8nubtrc74VU-14e9fhoUgZUlvn4bUDZdnDqNq6qTU1Hk_ZWdSa8lgzxX45cUVZJ9UQgqQyB3VBxztDE3rxvtK_1YEKNXTBUdpsRtJDyg-mNRDgB6MoFO0uBQC9bFLByETlVnvYzuanMwOZHP33ePsNUK8_nGKsNbDXCva4nv-Qz704PlAG-Cj9fDflVSKsspxkFZVBgCA2qabGBJVRqDUJf2rG-IYRCjW_09lOF5IhgJx7Yp58UtGWTOV7dCLm39nzHY0t68Wxu50qupfF3QZZd-QfMFXEjNn2-aAu-00Z6O_T31f_qjXaMSOehvCzcQxSQ0cWSsN6gevB-UkVEMOwaY2A4bpMz45E-H1-Bpo5IqpJs-64_dW7M3L2QOIV2gZZX5Quh9MBhi6UC5dcIt1uy53xFdRWxv3jGNxmDKNrLWqqtT1T6R1RXwYfLh6FUI9s4QY6Q89gH-UCbC1GgswyAyzaREv3D7hHM7yl8EgZuXfK34av4WWiBirNv-8ewIVa3RbNP7-x1B6MhCBMg-2Wl_3gPHBpwnPl8vhUmThjXQ9yqKpeUKuU4C0C_VXsU21ANdsRvraKqp3ArxxkumICBRmxlxH-RQ54dt2bzTzk7JBxHRAKdc1Sv4rwgNx0FjDff1F08kKqKpRxq61wDTxwm4P080C0ks5XOf5iJl)
.

 

Terms used but not defined in this announcement have the same meaning as set
out in the CompanyÕs announcement released at 7:00 a.m. on 15 April 2025.

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com (mailto:ir@maxcyte.com)

 

US Media Relations

Spectrum Science

Jordan Vines

+1 540-629-3137

jvines@spectrumscience.com (mailto:jvines@spectrumscience.com)

 

Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Mark Rogers

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

 

UK IR Adviser

ICR Healthcare

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@icrheatlhcare.com (mailto:maxcyte@icrheatlhcare.com)

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCIRMPTMTTTMAA